NCT01158079 - Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2012

Conditions

Solid Tumors

Interventions

DRUG

ALN-VSP02

The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study

Trial Locations (10)

Memorial Sloan-Kettering Cancer Center, New York

Sarah Cannon Research Institute, Nashville

Hospital Virgen del Rocio, Seville

Hospital Clinico Universitario de Valencia, Valencia

Karmanos Cancer Center, Detroit

TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

Beth Israel Deaconess Medical Center, Boston

Hospital Universitario Vall d'Hebron, Barcelona